Our aim to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Vaccines Research and Development.
To provide a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent solutions adopted in the fields of Vaccines Research and Development.
April 28, 2021
Early Bird Registration
April 27, 2021
August 26-28, 2021
Conference Chair Welcome Message:
On behalf of the Organizing Committee, it is our pleasure to welcome all participants to the Global Conference on Vaccines, Vaccines – 2021 to be held in Paris, France, August 26 – 28, 2021. Vaccines have taken center stage. The response to the COVID-19 pandemic has seen an unprecedented explosion in R&D, cooperation and collaboration. We see new ideas, new approaches and new vaccines. The global pace is breathtaking! We welcome all organizers, experts in the field, delegates, speakers and students. We especially encourage young researchers to present their recent research and to interact with other co-participants. Join us in Paris, the city of Louis Pasteur.
Let's enjoy the City of Lights and unique culture of Paris!!
The conference aims to empower future generations in different fields of Vaccinology to explore exciting research outcomes that lie in tune with the objectives and theme of this exciting event. It further helps you enhance your understanding of commercial, scientific and regulatory issues that affect strategic decision making in the Vaccine Sector.
This global conference sets the stage for brain-storming discussions among the participants with its enriching Q&A sessions, round table discussions and technical workshops and provides know-how of the latest methodologies and technicalities of Vaccines. Inspiring and educating talks from eminent scientists together with keynote lectures, plenary sessions, and video and poster presentations that span across the length and breadth of this conference.
We look forward to seeing you at Vaccines Conference-2021 in Paris, France.
Guidelines for the Abstract Submission:
1. The acceptable word range for the abstract is 150 – 250 words.
2. The abstracts which do not meet this word limit will be sent back to the author's to be revised.
3. The abstract content should be in English.
4. Please send with brief biography together with the Abstract.
5. Submit your abstract to (firstname.lastname@example.org) mail Id.
6. After submission you will be acknowledged with the acceptance letter via an email within 2-3 working days.
Director-Max Planck Institute for Infection Biology, Germany
Director Emeritus at Max Planck Institute for Infection Biology, Berlin, and at Max Planck Institute for Biophysical Chemistry, Göttingen, Germany. Founding Director (1993), Director of Department of Immunology at Max Planck Institute for Infection Biology, Berlin (1993 to 2019). Professor of Microbiology and Immunology, Charité University Clinics Berlin, Germany. Faculty Fellow of Hagler Institute for Advanced Study at Texas A & M University, College Station, Texas. Studied biology at Johannes Gutenberg University of Mainz, Germany, 1977 PhD (highest degree, summa cum laude). From 1987 to 1991 Professor for Medical Microbiology and Immunology, and from 1991 to 1998 Full Professor for Immunology at University of Ulm. Doctor Honoris Causa from Aix-Marseille University. Fellow of Royal College of Physicians of Edinburgh (FRCP Edin). Honorary Professor of Universidad Peruana Cayetano Heredia, Lima, Peru; Guest Professor at Tongji University, School of Medicine, Shanghai, China; Visiting Professor at Peking Union Medical College, Beijing, China.
Editor-in-Chief- DDTR JournalSpain
Maria Jose Alonso’s lab has pioneered numerous discoveries in the field of Pharmaceutical Nanotechnology and nanomedicine. She has coordinated several research consortia financed by the WHO, the Gates Foundation and the European Commission. She is the author of 290 scientific contributions with more than 30,000 cites (H factor 75/93). Because of the quality of her scientific articles she has been among the TOP TEN in Pharmacology (Times Higher Education international ranking, 2010). Recently, she become part of the “Power List” of the most influential researchers in the field of Biopharmaceuticals (The Medicine Maker, 2020). She has received 33 awards, among them the ” Research and Education Excellence Medal” granted by the Spanish Government, the“Jaime I Award”, the General Council of Pharmacy Medal, and other awards granted by scientific organizations, such as the ”Marie Junot Award” of the APGI, the “Founders Award”, the “Outstanding Service Award” and the “Women in Sciences Award” of the CRS. She was also recently awarded by the AIM-HI Women’s Venture Competition program born out of the National Foundation for Cancer Research (NFCR). She is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and a Fellow of the Controlled Release Society, a member of the Royal Academy of Pharmacy of Spain (RANF), the Royal Academy of Sciences of Galicia, the Royal Academy of Pharmacy in Galicia and a member of theRoyal Academy of Medicine of Belgium and also a member of theUS National Academy of Medicine (NAM).She was the Vice-rector of Research and Innovation of the USC (2006-10).
Dr. Sherry Layton received her Ph.D. from the University of Arkansas where she studied poultry science. Her early career research in poultry immunology and molecular engineering set the foundation for her pioneering scientific successes in animal health. Over the last decade Dr. Layton developed and patented an innovative orally administered inactive sub-unit vaccine platform (One Health Vaccine Platform), Biotech Vac. This research and development led to the recent introduction of Biotech Vac – Salmonella in Latin America, which provides poultry with immunological protection from all mobile Salmonella species, a first in the poultry industry, and will help reduce the risk of food-borne Salmonellosis in humans. Currently, she serves as CEO for Vetanco USA and Chief Scientific Officer for Vetanco International/BV Science, a global animal health and nutrition company where her research focuses on maintaining animal health and ensuring food safety naturally .Dr. Layton currently leads a research team of veterinarians and scientists in the U.S. and South America and has developed a pipeline of pioneering and effective vaccines. She is currently focused on supporting the introduction of Biotech Vac – Salmonella and Biotech Vac Coccidia in Latin America as well as establishing biologicals in the U.S. market with the newly formed Vetanco USA.
Head-Virology Agri-Food and Biosciences Institute United Kingdom
Professor S. Louise Cosby is a graduate (B.Sc. and Ph.D. in Microbiology) of Queen’s University Belfast and was a member of staff for over 30 years. She held the post of Chair of Microbiology in the School of Medicine Dentistry and Biomedical Sciences from 2002 to 2015. She is currently Head of Virology Branch at the Agri-Food and Biosciences Institute in Belfast and emeritus/honorary Professor at Queen's University Belfast. Professor Cosby is a Fellow of the Royal College of Pathologists (London) and a Fellow of the Royal Society of Biology (UK). In 1985 she was a visiting Associate Professor in Cornell University USA and has been an occasional visiting scientist at the Pirbright Institute, UK. Professor Cosby is an editor for 'Vaccines' and 'Frontiers in Microbiology'.
Research Director, National Institute of Health and Medical ResearchFrance
Camille Locht, PhD, holds currently a position as Research Director at the French National Institute of Health and Medical Research (Inserm) and was the founding director of the Center for Infection and Immunity of Lille at the Institut Pasteur de Lille. He has obtained his PhD at the Catholic University of Leuven, Belgium, in 1984. After a 3-years post-doctoral stay at the National Institute of Allergy and Infectious Disease, USA, where he started to work on pertussis and cloned the pertussis toxin genes, he joined SmithKline-Beecham (now GSK) to help developing acellular pertussis vaccines. Since 1989 he is the head of a research laboratory at the Institut Pasteur de Lille, where he has been the Scientific Director from 2002 to 2013. His research interest is in molecular pathogenesis of respiratory infections, essentially pertussis and tuberculosis, with the long-term aim to develop new tools to combat these diseases. A very powerful molecular typing system for mycobacteria, invented in his laboratory has already reached the market, and a live attenuated nasal pertussis vaccine has now successfully completed phase I trials and is currently in phase II. He also has discovered a protective mycobacterial latency antigen, called heparin-binding haemagglutinin (HBHA), which appears to be a powerful tool for the diagnosis of latent tuberculosis and for risk stratification of latently infected subjects. He has authored close to 350 international publications, book chapters and patents and has obtained several research awards.
Scientist-Institute of Immunology and Experimental Therapy PAS Poland
Dr. Wieslaw Swientnicki is a Biochemist/Molecular Biologist working on bacterial virulence systems. His Main interests are type III secretion systems(T3SS) from EPEC, Y. pestis and P. aeruginosa. The second interests are antibacterials, therapeutics and prophylactics, for human pathogens. The work involves a lot of bioinformatics and computational chemistry methods to design small molecules blocking vital components of pathogens’ metabolism. For vaccines, the work involves a lot of synthetic and systems biology as tools to design next generation of bacterial vaccines.
Sechenov University Russia
Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences. In 2001, maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1985 through 1987, worked as a Post Doc Research Associate, for Institute of Medical Enzymology; from 1987 through 1989, was a Senior Research Associate, Koltzov Institute of Developmental Biology, USSR Academy of Sciences. From 1989 through 1995, was a Head of the Lab of Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. In 1989, trained at the Lab of Immunology, NEI, Bethesda, MD, USA,, NIH and Lab of Immunology, Wills Eye Hospital, Philadelphia, USA, as well as at some of the British Universities on the invitation of the Royal Society for Immunology. From 1995 through 2004, was a Director of the Dept for Immu-nology, Moscow Clinical Research Institute (MONIKI).
Head-Zabludowicz Center for Autoimmune Diseases Israel
Yehuda Shoenfeld is the founder and head of the Zabludowicz Center for Autoimmune Diseases, at the Sheba Medical Center, which is affiliated to the Sackler Faculty of Medicine in Tel-Aviv University, in Israel. Professor Shoenfeld is also the Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at the Tel-Aviv University. Professor Shoenfeld’s clinical and scientific works focus on autoimmune and rheumatic diseases, and he has published more than 2000 papers in journals such as New Eng J Med, Nature, Lancet, Proc Nat AcadScie, J Clin Invest, J Immunol, Blood, FASEB, J Exp Med, Circulation, Cancer and others. His articles have had over 65,000 citations. He has written more than 350 chapters in books, and has authored and edited 35 books, some of which became cornerstones in science and clinical practice, such as "The Mosaic of Autoimmunity", "Infections and Autoimmunity" and the textbook "Autoantibodies" and "Diagnostic criteria of autoimmune diseases", all of which were published by Elsevier and sold thousands of copies. Professor Shoenfeldis on the editorial boards of 43 journals in the field of rheumatology and autoimmunity and is the founder and the editor of the IMAJ (Israel Medical Association Journal) the representative journal of science and medicine in the English language in Israel, and also is the founder and Editor of Autoimmunity Reviews (Elsevier) (Impact factor 8.9) and co-Editor of the Journal of Autoimmunity (Impact factor 8).For the past twenty years Yehuda has been the Editor of “Harefuah” – The Israel journal in medicine (Hebrew).
CEO & CSO - Verndari, Inc. USA
Dr. Daniel Henderson is a co-founder, chief executive officer and chief scientific officer of Verndari, Inc., a biopharmaceutical company based in Napa, California, that aims to transform global health through vaccine science. Prior to Verndari, Dr. Henderson co-founded and served as president of PaxVax, a company based in Redwood City, California, focused on developing, manufacturing and commercializing specialty vaccines to protect against existing and emerging infectious diseases, such as typhoid, cholera and hepatitis A for travelers to countries without adequate water sanitation. Separately, PaxVax worked on anthrax vaccines for the U.S. military.While at PaxVax, Dr. Henderson was the named principal investigatoron a virus vectored oral bird flu vaccine (H5) with funding of $10 million for a phase one clinical trial (Wellcome Trust HN-#704483, 2008). PaxVax was later sold to Emergent BioSolutions in 2018.In 2016, PaxVax was named Best Early-Stage Vaccine Biotech company at the 16th annual World Vaccine Congress in Washington, D.C. Dr. Henderson was the founder, president and CEO of Calydon, a private U.S. biotechnology company located in Sunnyvale, California, which focused on developing therapeutics for cancer. At Calydon, which was sold to Cell Genesys in 2004, he patented a method for genetically engineering an adenovirus targeting prostate cancer. Dr. Henderson has been recognized as one of two pioneers in the field of oncolytic virotherapy (Nettelbeck, D., October 2003 and July 2008, Tumor Busting Viruses, Scientific American). Dr. Henderson was also founder, president and CEO of Microgenics Corporation. At Microgenics, Dr. Henderson, invented the groundbreaking CEDIA™ immunoassay system, a bioanalytical method that uses the specificity of an antigen-antibody reaction to detect molecules in biological samples. Microgenics was acquired by Boehringer Mannheim in 1991, which in turn was bought by Roche. The SEC required Roche to sell certain CEDIA products, which resulted in a rebirth of Microgenics that was later acquired by Thermo Fisher Scientific. In 2015, Dr. Henderson was awarded the biennial Ullman Prize for Technology Innovation by the American Association for Clinical Chemistry for this groundbreaking work developing the CEDIA™ system. More than $1 billion of CEDIA™ tests are now sold annually, the majority by Roche, with a significant component from Thermo Fisher Scientific.
President & CEO-Human Vaccines Project New York
Wayne C Koff, PhD., is the founding President and CEO of the Human Vaccines Project, a non-profit R&D consortium focused on decoding the human immune system to accelerate vaccine and therapeutic development. In 2019, Dr. Koff was named by Foreign Policy along with Barack and Michelle Obama, Bill and Melinda Gates, Angela Merkel and others as one of the 100 Global Thinkers who have “ had a profound impact on the planet in the last 12 months.” As of July 2020, Dr. Koff is also Adjunct Professor, Dept. of Epidemiology, Harvard TH Chan School of Public Health. Prior to joining the Project, Koff served as CSO and Sr. VP, R&D at the International AIDS Vaccine Initiative (IAVI), leading IAVI’s research and development program. At IAVI, his accomplishments included developing multiple HIV vaccines through clinical trials; establishing state-of-the-art laboratories in the U.S., Europe, India and Africa; conducting the first HIV vaccine trials in India, Kenya and Rwanda; and establishing the Neutralizing Antibody Consortium, which identified broad and potent neutralizing antibodies against HIV that are currently in commercial development. Dr. Koff has published over 100 scientific papers and edited eight books on vaccine development.
CEO-Food and Drugs Authority Accra - Ghana
Delese Mimi Darko is a pharmacist by profession with a Master’s degree in Business Administration from the University of Northampton. Her 28 year carrier encompasses the regulation of food and drugs including clinical trials regulation, marketing authorization and post approval safety monitoring of medicines and cosmetics, household chemicals and medical devices. She has risen through the ranks of the Food and Drugs Authority to become the first female Chief Executive Officer in 2017. She led the FDA process of designation by the NEPAD/African Medicines Regulation Harmonization (AMRH) as a Regional Centers of Regulatory Excellence in 3 very critical areas, namely, Medicines Safety (pharmacovigilance), Clinical Trials and Drug Registration. Mimi Chairs the WHO African Vaccines Regulatory Forum and serves on several international and local advisory committees and bodies. She has received several awards for her exemplary and commendable work.
GSK Vaccines Belgium
After a PhD in the field of proteomics of cellular ageing and a post-doc in proteomics, Jean-Francois Dierick entered the Pharmaceutical world. First for SGS, a CRO, where he was leading the Biology Department (Biotechnology, Biochemistry, Cell Biology, Molecular Biology, Microbiology, Toxicology). Then he joined GSK Vaccines where he has occupied several positions related to analytics of biological products both in the development and the commercial areas. Today he is working at GSK Vaccines' Global QC as Global Subject Matter Expert for Analytical Method Validation and Transfer. He is leading or involved in several programs related to the improvement of the Life Cycle management of analytical methods.
Head-Analytical R&D GSK Vaccines Belgium
Claudia is head of the Global platform for Separations in Analytical R&D GSK Vaccines, located in Belgium, Italy and US, leading the technical teams to advance vaccine candidates from late discovery through clinical development phases. She held a PhD in Biochemistry and Biophysics, and professionally shaped in the R&D environment for analytical development and structural characterization of biomolecules. She joined GSK from Novartis Vaccines in 2015, where formerly covered the role of Product and Process Development Leader for Bexsero Vaccine and leaded the Analytical Biophysic group in ARD Italy.
University of Maryland USA
Dr. Fuerst is a professor in the Department of Cell Biology and Molecular Genetics, University of Maryland (UMD). He also served as director of the Institute for Bioscience and Biotechnology Research (IBBR), UMD, in which the Institute’s mission is focused on biomolecular structure-function relationships and measurement sciences with an emphasis on structure-based vaccine design, next generation protein therapeutics, and macromolecular delivery systems. Dr. Fuerst has over three decades of research and development experience in vaccines and immunotherapeutics. At UMD-IBBR, his current research is focused is on hepatitis C virus, ebolavirus, and SARS-CoV-2, and development of a novel therapeutic approach to specifically target and cleave cancer oncogene targets. Prior to joining UMD, he was a founding scientist at MedImmune and later joined the U.S. Department of Health and Human Services as director of vaccines and biologics in the Office of the Secretary. In this capacity, he helped establish and lead the Biomedical Advanced Research and Development Authority (BARDA) responsible for the development and acquisition of vaccines and immunotherapeutic products for biodefense and other emerging public health threats. Early in his career, he served as a senior fellow at the National Institutes of Health, National Institute of Allergy and Infectious Diseases. He holds a BA in biochemistry from the University of California at Berkeley, a PhD in molecular genetics from Cornell University, and a MBA in science, technology, and innovation from the George Washington University.
National Autonomous University of Mexico-Mexico
Professor Alejandro de la Pena-Moctezuma is a Full-time Professor “C”, lecturer in Animal Bacterial and Mycotic Diseases. He has more than 35 years of teaching experience at the School of Veterinary Medicine, Universidad Nacional Autnoma de México (National Autonomous University of Mexico), currently affiliated at the Altiplano Husbandry reaching Research an Extension Center (CEIEPAA), in Tequisquiapan, Querétaro. He is a research leader in the Epidemiology of Veterinary Leptospirosis and vaccinology of Leptospira. His research interest is focused on the secretine GspD of Leptospira as a potential protective antigen against leptospirosis.
University of South Florida USA
Dr. Sun is an Associate Professor with tenure in the Department of Molecular Medicine, College of Medicine at the University of South Florida (USF). He holds secondary appointments in the Department of Internal Medicine, Department of Cell Biology, Microbiology & Molecular Biology, Department of Chemistry at USF, and USF Genomics. He received his PhD in Natural Sciences from the University of Kiel, Germany, and his Master Degree in Veterinary Microbiology and Immunology from the Nanjing Agricultural University, China. He received his postdoctoral training in Molecular Microbiology and Biochemistry at Brown University, USA. The research in his laboratory is focused on the pathogenesis of Clostridiodes difficile and development of novel therapeutics to prevent/treat C. difficile infection (CDI). He is leading a research team at USF to develop vaccines against CDI. He is a NIH Career Development Awardee. His research is supported by several NIH grants. He has been actively serving NIH study section panels including chairing the NIH study section panel. He serves as an Associate Editor for “Molecular Medicine”, a topic editor for “Frontiers in Microbiology”, and editorial boards for “Infection and Immunity” and “Applied and Environmental Microbiology”. He chaired Research Committee of College of Medicine at USF in 2020. In 2018, he was awarded "Faculty Outstanding Research Achievement Award" at USF. In 2019, he was awarded "Excellence in Innovation Award".
University of Rosario Colombia Colombia
CARMEN TERESA is a Vet and she has master’s degree in science focused on Pharmacology at Universidad Nacional de Colombia. Her work focused on topic in pharmacology and recently in vaccine in veterinary. Actually she is a candidate at Doctor Program in Biomedical and Biological Sciences of Universidad del Rosario Colombia, her research focused in the study of response of the complex class II in swine against some zoonotic pathogen.
Director-Centre for Neuroendocrinology UK
Professor Robert (Bob) Millar grew up in Zimbabwe and studied Zoology, Botany and Chemistry at the University of the former Rhodesia and Nyasaland. He then obtained a master’s degree in Biochemistry in London and a PhD in reproductive biology in Liverpool before moving into human biomedical research at the University of Cape Town where he became Professor ad hominem and directed four MRC Units. For twelve years he served as Director of the prestigious MRC Human Reproductive Sciences Unit at the University of Edinburgh, UK, and in 2011 he joined the University of Pretoria to take up the Directorship of the Mammal Research Institute. He stepped aside from this position in 2016 to take up his current role as Director of the Centre for Neuroendocrinology, in the Faculty of Health Sciences. Prof Millar is also Senior Research Fellow at the University of Cape Town, and is a Research Fellow at the Centre of Integrative Physiology at the University of Edinburgh and Emeritus Professor at the University of St Andrews. His research spans a wide spectrum including comparative reproductive biology and physiology, modular biology of receptor function, drug development and “first in man” clinical research. Professor Millar is the recipient of a number of prestigious awards, not least the Harry Oppenheimer Fellowship which is widely considered to be the premier award for research on the African continent. Recently, he was also recipient of the John F Herschel Medal, (the highest award of the Royal Society of South Africa) and the MRC South Africa Platinum Medal.
GSK Vaccines Belgium
Phu Nguyen holds a PhD in Biosciences Engineering with a strong academic research background in bacterial transcription regulation and protein sciences. Her journey in pharma has mainly involved projects in R&D and quality processes implementation. Currently, she is leading the development and implementation of the Continued Method Verification process for analytical monitoring of QC testing in GSK.
Head-Recombinant Vaccine GroupNCI, NIH USA
Dr. Hodge is a Senior Investigator and head of the Recombinant Vaccine Group in the Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, MD. Dr. Hodge received his Ph.D. in Comparative and Experimental Medicine from the University of Tennessee, and his MBA from the George Washington University. He was awarded tenure in 2016. Dr. Hodge is active in the area of tumor immunity, and has made significant contributions to the design and development of novel recombinant vaccines and vaccine strategies for cancer immunotherapy including a) recombinant vectors to deliver tumor antigens, b) the use of costimulation to enhance antitumor T-cell responses, c) the combined use of vaccines with radiation, chemotherapy, and targeted small-molecule therapeutics. The concepts and therapeutics developed within the Recombinant Vaccine Group have been translated into many randomized multi-center trials at numerous Cancer Centers.
GSK Vaccines Belgium
Shahjahan Shaid (M) has been trained as biologist in the field of immunology, genetics, animal experiments and replacements alternatives like the MAT to the Rabbit pyrogen test at the University of Konstanz, Germany. His PhD at the University of Berlin, Germany and Robert Koch Institut focused on antibody design and diagnostic of highly infectious pathogens in BSL3 laboratories. Since 2013 he is committed to the development of methods for routine testing under GMP conditions within GSK Vaccines. In 2016 he took the lead of the GSK Vaccines 3R Program as well as their contribution to collaborative studies as Vac2Vac or BSPs.
Cornell University New York
Kathleen Hefferon received her PhD from the Department of Medical Biophysics, University of Toronto and currently teaches microbiology at Cornell University. Kathleen has published multiple research papers, chapters and reviews, and has written three books. Kathleen is the Fulbright Canada Research Chair of Global Food Security and has been a visiting professor at the University of Toronto over the past year. Her research interests include the use of biotechnology to promote global health.
Senior Principal Scientist Indian Institute of Chemical Technology-India
Halmuthur.M.Sampath Kumar, Medicinal Chemist and Immunologist, graduated from chemistry department Gulbarga University, India securing first rank and a gold medal in 1986, obtained his Ph.D degree in biological Chemistry(1995)from CSIR-Indian Institute of Chemical Technology, Hyderabad. He continued research on various aspects of agrochemical and pharmaceutical technology development at Indian Institute of Chemical Technology, Hyderabad. . His team was instrumental in developing cost effective technology for several drugs and agrochemicals which are successfully commercialized in India and abroad. Dr. Kumar successfully completed collaborative projects with various reputed multinationals like P&G and Colgate Palmolive in the area of cosmeceuticals and oral care products. Apart frm medicinal chemistry, Dr. Kumar worked in the area of combinatorial Chemistry and development of new synthetic methods, organometallic chemistry, green chemistry and synthesis of complex carbogenic molecules. His work in the afore mentioned areas led to several publications in reputed international journals and his efforts in basic and applied areas of organic synthesis won him several awards and recognitions. As Alexander von Humboldt Fellow, he worked in Max Planck Institute for Molecular physiology at Dortmund in the year 2000-2002 on gene therapy and at Friedrich-Alexander-Universität, Erlangen-Nürnberg in 2019 to work in Tsogoeva’s lab on Hybrid drugs and tumor homing peptide conjugates of anticancer drugs. Dr. Kumar had been the chairman of the Department of Synthetic and Biological Chemistry(presently rechristened as Medicinal Chemistry) at IIIM-Jammu dedicated to medicinal Chemistry research. Currently Dr .Kumar is the nodal scientist for the Vaccine immunology programme at CSIR-IICT, Hyderabad, where his focus is on the development of novel vaccine and delivery vehicles, vaccine(Th1) adjuvants, designer small molecule immunomodulators based on natural product scaffolds.
Rutgers – New Jersey Medical School USA
Hua Zhu obtained Ph.D. degree from Columbia University and completed his postdoctoral studies from Princeton University. He is associate and tenure professor in Rutgers – New Jersey Medical School, USA. He has been working on herpesviruses for over 25 years. He started with studying human cytomegalovirus (HCMV) immediate-early gene function. He performed pioneer works on global cellular transcriptional responses to viral infection using differential display and gene chip technology. One important discovery from these studies is how HCMV infection activates large numbers of interferon-stimulated genes. Later, he applied the bacterial artificial chromosome (BAC) technology to study HCMV and varicella zoster virus (VZV) gene function, tropism and pathogenesis. He is one of the first to construct for HCMV and VZV BACs.He also used humanized mouse model and luciferase assay to study viral replication in vivo. He was first to discover VZV neurotropic factor which leads to a novel neuro-attenuated VZV vaccine candidate development. He also used CMV as gene deliver vectors. He has published over 90 research articles, reviews and book chapters.
Medical Acupuncture and Pain Management Clinic Brazil
Huang Wei Ling, born in Taiwan, raised and graduated in medicine in Brazil, specialist in infectious and parasitic diseases, a General Practitioner and Parenteral and Enteral Medical Nutrition Therapist. Once in charge of the Hospital Infection Control Service of the City of Franca’s General Hospital, she was responsible for the control of all prescribed antimicrobial medication and received an award for the best paper presented at the Brazilian Hospital Infection Control Congress in 1998. Since 1997, she works with the approach and treatment of all chronic diseases in a holistic way, with treatment guided through the teachings of Traditional Chinese Medicine and Hippocrates. Researcher in the University of São Paulo, in the Ophthalmology department from 2012 to 2013.